NPM1 (21.7%), FLT3-ITD (20.3%), CEBPA (18.4%), NRAS (17.0%), TET2 (16.4%), and DNMT3A (16.4%) were the most common mutations in AML. This evidence concerns the gene NRAS and acute myeloid leukemia.